Ann: Review of 2020 and outlook, page-36

hoping there will be a presentation from the new CEO, Dr. Gourlay for his strategy and direction....

Dr Gourlay has more than 30 years of experience in the development of novel therapeutics and brings
considerable skills and experience to Actinogen as the Company moves into further clinical development of
its lead compound Xanamem. Formerly the founding Chief Medical Officer (CMO) at US-based Principia
Biopharma Inc., Dr Gourlay was responsible for the supervision of multiple pre-clinical, first-in-human, Phase
2 and 3 clinical trial programs for four small molecules in orphan immunological diseases, multiple sclerosis
and cancer. The data generated by these trials, and Dr Gourlay’s roadshow presentations, supported a
successful NASDAQ IPO of Principia Biopharma Inc. in 2018 - subsequently followed by an acquisition of by
Sanofi for US$3.7B in 2020

dyor